Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | LHCGR | P22888 | 3/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439863 | 0.79 | HHAT (0.48) | HHATMAPK1NPSR1LHCGRDRD1 | |
| SCHEMBL4018143 | 0.79 | HHAT (0.48) | HHATMAPK1NPSR1LHCGRDRD1 | |
| SCHEMBL1499097 | 0.79 | HHAT (0.48) | HHATMAPK1NPSR1LHCGRDRD1 | |
| Bromide SCHEMBL4019730 | 0.78 | HHAT (0.47) | HHATMAPK1NPSR1LHCGRDRD1 | |
| Hydrochloric Acid SCHEMBL5239130 | 0.78 | HHAT (0.47) | HHATMAPK1NPSR1LHCGRDRD1 | |
| SCHEMBL4738266 | 0.75 | HHAT (0.48) | HHATMAPK1NPSR1LHCGRDRD1 | |
| SCHEMBL2307868 | 0.75 | HHAT (0.48) | HHATMAPK1NPSR1LHCGRDRD1 | |
| Sulfuric Acid SCHEMBL2306919 | 0.72 | HHAT (0.45) | HHATLHCGRDRD1ABCB11 | |
| Hydrochloric Acid SCHEMBL11552953 | 0.69 | MAPK1 (0.51) | HHATMAPK1NPSR1LHCGRDRD1 | |
| SCHEMBL5303682 | 0.69 | HHAT (0.52) | HHATMAPK1NPSR1LHCGRDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353928-B1 | PROCESS FOR PREPARING CLOPIDOGREL | CADILA HEALTHCARE LTD (IN) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006003671-A1 | A PROCESS FOR RESOLUTION OF METHYLAMINO(2-CHLOROPHENYL)ACETATE | BATTULA SRINIVASA REDDY (IN) | 2006-01-12 | — | — | WO | disclosed |
| US-20050049415-A1 | Process for preparing enantiomerically pure alpha phenyl-alpha (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic acid derivatives | MERCK GENERICS (UK) LIMITED (GB) | 2005-03-03 | — | — | US | disclosed |
| EP-1438314-A1 | A PROCESS FOR PREPARING ENANTIOMERICALLY PURE ALPHA-PHENYL-APLPHA(6,7-DIHYDRO-4H-THIENO 3,2-C PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES | Merck Generics (UK) Limited (GB) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003035652-A9 | A PROCESS FOR PREPARING ENANTIOMERICALLY PURE α-PHENYL-α-(6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES | MERCK GENERICS UK LTD (GB) | 2004-04-08 | — | — | WO | disclosed |
| EP-1353928-A2 | PROCESS FOR PREPARING CLOPIDOGREL | CADILA HEALTHCARE LTD. (IN) | 2003-10-22 | — | — | EP | disclosed |
| US-6635763-B2 | From 2-chlorobenzaldehyde and cyanide compound, then amine; resolution of racemic mixture | CADILA HEALTH CARE LIMITED (IN) | 2003-10-21 | — | — | US | disclosed |
| WO-2003035652-A1 | A PROCESS FOR PREPARING ENANTIOMERICALLY PURE α-PHENYL-α-(6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES | MERCK GENERICS [UK] LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
| US-20020177712-A1 | Process to prepare clopidogrel | CADILA HEALTHCARE LIMITED (IN) | 2002-11-28 | — | — | US | disclosed |
| WO-2002059128-A2 | PROCESS FOR PREPARING CLOPIDOGREL | CADILA HEALTHCARE LTD. (IN) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177712-A1 | Process to prepare clopidogrel | PTGER3, P2RY13, P2RY4 | HHAT 2712/4885MAPK1 2655/4885NPSR1 697/4885 |
| US-20050049415-A1 | Process for preparing enantiomerically pure alpha phenyl-alpha (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic acid derivatives | NR1H3, NR1H2, NR1H4 | HHAT 3434/4885MAPK1 1972/4885NPSR1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.